title: New molecularly targeted therapies for glioblastoma multiforme.
abstract: Glioblastoma multiforme (GBM) is the most malignant brain tumor in adults, exhibiting high mortality. Standard therapy (surgery, radiotherapy and chemotherapy with temozolomide) has only limited effectiveness. The progress in genomics regarding GBM, in the detection of new markers of oncogenesis, abnormalities in signalling pathways, tumor microenvironment, and pathological angiogenesis over the past decade are briefly discussed. The role of novel prognostic in this review biomarkers [isocitrate dehydrogenases 1 and 2, CpG island methylator phenotype, promoter methylation status of the MGMT (O-6-methylguanine-methyltransferase) gene] is also discussed. New targeted therapeutic approaches are classified into several functional subgroups, such as inhibitors of growth factors and their receptors, inhibitors of proteins of intracellular signaling pathways, epigenetic gene-expressing mechanisms, inhibitors of tumor angiogenesis, tumor imunotherapy and vaccines. Finally novel possibilities for GBM treatment are summarized in this review.
authors: Department of Neurology, Faculty Hospital in Pilsen, Alej svobody 80, 304 60 Pilsen, Czech Republic. polivka@fnplzen.cz
authors: Jiri
authors: J
authors: Polivka
authors: Jiri
authors: J
authors: Polivka
authors: Vladimir
authors: V
authors: Rohan
authors: Ondrej
authors: O
authors: Topolcan
authors: Jiri
authors: J
authors: Ferda
mesh_terms: D001932:Brain Neoplasms / Q000188:drug therapy / Q000628:therapy*; D015316:Genetic Therapy; D005909:Glioblastoma / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy